Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer
- 2 November 2019
- journal article
- review article
- Published by Taylor & Francis in Growth Factors
- Vol. 37 (5-6) , 209-225
Abstract
The discovery of epidermal growth factor (EGF) and its receptor (EGFR) revealed the connection between EGF-like ligands, signaling from the EGFR family members and cancer. Over the next fifty years, analysis of EGFR expression and mutation led to the use of monoclonal antibodies to target EGFR in the treatment of metastatic colorectal cancer (mCRC) and this treatment has improved outcomes for patients. The use of the RAS oncogene mutational status has helped to refine patient selection for EGFR antibody therapy, but an effective molecular predictor of likely responders is lacking. This review analyzes the potential utility of measuring the expression, levels and activation of EGF-like ligands and associated processes as prognostic or predictive markers for the identification of patient risk and more effective mCRC therapies.Keywords
This publication has 144 references indexed in Scilit:
- A Comprehensive Survey of Ras Mutations in CancerCancer Research, 2012
- Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locationsCancer Letters, 2012
- Amphiregulin Exosomes Increase Cancer Cell InvasionCurrent Biology, 2011
- Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancerBritish Journal of Cancer, 2011
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder CancerJournal of Urology, 2008
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997